Search Result

Results for "

Btk

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Btk (203) ADC Payload (1) Antibiotic (1) Apoptosis (13) Autophagy (1) BCRP (1) BMX Kinase (2) ByeTAC (1) c-Kit (1) c-Met/HGFR (1) CDK (1) CXCR (1) Cytochrome P450 (2) Dengue Virus (2) DNA/RNA Synthesis (1) Drug Intermediate (1) Drug Metabolite (2) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (5) EGFR (9) Epigenetic Reader Domain (1) FAK (1) Flavivirus (2) FLT3 (4) Fluorescent Dye (1) Glutathione S-transferase (1) Insulin Receptor (1) IRAK (2) Isotope-Labeled Compounds (4) Itk (6) JAK (11) LAG-3 (1) Ligands for E3 Ligase (4) Ligands for Target Protein for PROTAC (12) MALT1 (1) MNK (1) Molecular Glues (1) Nuclear Factor of activated T Cells (NFAT) (1) p38 MAPK (1) PD-1/PD-L1 (1) PI3K (1) Polo-like Kinase (PLK) (2) PROTAC Linkers (6) PROTAC-Linker Conjugates for PAC (1) PROTACs (27) Pyroptosis (1) RANKL/RANK (1) Reference Standards (3) RET (1) Small Interfering RNA (siRNA) (3) Src (2) Toll-like Receptor (TLR) (3) Topoisomerase (1) Tyrosinase (1)
By Research Areas:	Cancer (169) Cardiovascular Disease (3) Endocrinology (1) Infection (5) Inflammation/Immunology (71) Metabolic Disease (4) Neurological Disease (5)
Click Chemistry:	PROTAC Synthesis (2) Azide (1) Alkynes (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

239

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Btk

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-125997

BTK inhibitor 10	Btk	Inflammation/Immunology
BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment .

HY-152201

BTK-IN-18	Btk	Cancer
BTK-IN-18 is a potent, reversible *BTK* inhibitor with an IC₅₀ of 0.002 µM. BTK-IN-18 inhibits both CD69 and CD86 in vivo .

HY-147580

BTK-IN-10	Btk	Cancer
BTK-IN-10 is a potent *BTK* inhibitor with IC₅₀s of <5 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022012509A1; example 111) .

HY-147582

BTK-IN-12	Btk	Cancer
BTK-IN-12 is a potent *BTK* inhibitor with IC₅₀s of 1.2 nM and 0.8 nM for wild-type BTK or mutated BTK (C481S), respectively (WO2022037649A1; compound 8) .

HY-141689

BTK-IN-3	Btk	Cancer
BTK-IN-3 (example 1) is an inhibitor of *BTK. BTK*-IN-3 can used to study cancer .

HY-158064

BTK-IN-36	Btk	Cancer
BTK-IN-36 (S-016) is a *BTK* inhibitor, with IC₅₀ of 0.5 nM. BTK-IN-36 can be used in cancer-related research .

HY-169307

BTK-IN-38	Btk	Cancer
BTK-IN-38 (Example 125) is a potent *BTK* inhibitor. BTK-IN-38 inhibits DOHH2 and BT474 cells proliferation with IC₅₀s of 114 and 340 nM, respectively .

HY-162081

BTK-IN-32	Btk	Cancer
BTK-IN-32 (compound C2) is a potent inhibitor of *BTK. BTK-IN-32 activates full-length BTK* and smaller multidomain BTK fragments instead of the isolated kinase domain .

HY-176172

BTK-IN-44	Btk	Cancer
BTK-IN-44 (Compound 10) is a potent noncovalent inhibitor of Bruton’s tyrosine kinase (BTK) with an IC₅₀ value of 24.7 nM. BTK-IN-44 interferes with signaling pathways of B cell malignancies, showing antitumor effects in lymphoma cells. BTK-IN-44 is promising for research of B cell malignancies (such as lymphoma) .

HY-162257

BTK-IN-34	Btk	Cancer
BTK-IN-34 (compound 9h) is a selective *BTK* inhibitor. BTK-IN-34 shows antiproliferative activity in RAMOS cells through selective inhibition of pBTK (Tyr223) without affecting Lyn and Syk, upstream proteins in the BCR signaling pathway .

HY-P10609

Btk substrate peptide	Btk	Others
Btk substrate peptide is a peptide substrate corresponding to residues 217-229 of human Bruton’s tyrosine kinase (Btk), of which the tyrosine at residue 223 is the major autophosphorylation site of *Btk. Btk* substrate peptide is used as a substrate in in vitro kinase assays to evaluate the activity of *Btk* or other tyrosine kinases .

HY-159956

BTK-IN-39	Ligands for Target Protein for PROTAC	Cancer
BTK-IN-39 (0204) is a PROTAC target protein ligand that can be used to synthesize PROTAC BTK Degrader-11 (HY-159947) .

HY-160141

Catadegbrutinib BGB-16673; Btk-IN-29	PROTACs Btk	Cancer
BGB-16673 (BGB-16673; BTK-IN-29) is an orally active, selectively chimeric degradation activator compound (CDAC), targeting *BTK* (IC₅₀=0.69 nM). BGB-16673 ligates BTK to E3 ubiquitin ligase, causing BTK to undergo polyubiquitination, which is then recognized and degraded by the proteasome, thereby exerting efficient BTK degradation activity. BGB-16673 can be used in the research of B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma .

HY-147584

BTK-IN-14	Btk	Inflammation/Immunology Cancer
BTK-IN-14 is a potent inhibitor of *BTK. BTK* plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .

HY-147581

BTK-IN-11	Btk	Inflammation/Immunology Cancer
BTK-IN-11 is a potent inhibitor of *BTK. BTK* plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2) .

HY-153705

BTK-IN-25	Btk	Cancer
BTK-IN-25 (compound 71) is a potent inhibitor of *BTK, and inhibits BTK(C481S) with an IC₅₀* value of 0.77 nM. BTK-IN-25 inhibits BTK in DOHH2 cells with an IC₅₀ value of 1 nM .

HY-150752

BTK-IN-15	Btk Pyroptosis	Cancer
BTK-IN-15 (compound 42) is a potent Bruton's tyrosine kinase (BTK) inhibitor with high oral absorption. BTK-IN-15 inhibits *BTK* with an IC₅₀ value of 0.7 nM. BTK-IN-15 displays excellent kinase selectivity, antitumor activity, and induces apoptosis .

HY-153951S

BTK-IN-26	Btk	Inflammation/Immunology Cancer
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC₅₀ values of 0.7 and 0.8 nM for *BTK* and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .

HY-159589

BTK-IN-37	Btk Apoptosis	Cancer
BTK-IN-37 (compound 8d) is a *BTK* inhibitor that can induce apoptosis in cancer cells. BTK-IN-37 targets BTK with K_i and IC₅₀ of 5.07 nM and 3.6 nM, respectively. BTK-IN-37 can also selectively induce enrichment of genes involved in necroptosis and pyroptosis .

HY-157159

BTK-IN-28	Btk	Cancer
BTK-IN-28 (compound PID-4) is a potent *BTK* inhibitor with anticancer activity. BTK-IN-28 has inhibitory effects on BTK and downstream signaling cascades and selectively inhibits Burkitt lymphoma RAMOS proliferation. BTK-IN-28 has no significant cytotoxicity towards non-tumor cells .

HY-172589

BTK-IN-43	Btk	Cancer
BTK-IN-43 (compound 9) is an inhibitor of *BTK* with an IC₅₀ value of 21.6 nM. BTK-IN-43 has oral activity .

HY-170324

BTK-IN-40	Btk	Others
BTK-IN-40 (compound 375) is a *BTK* inhibitor .

HY-156553

BTK-IN-27	Btk	Inflammation/Immunology Cancer
BTK-IN-27 (example 8) is a *BTK* inhibitor (IC₅₀: 0.2 nM). BTK-IN-27 shows anti-proliferative activity in TMD8 cells (IC₅₀: < 5 nM). BTK-IN-27 can be used for research of cancer, lymphoma, leukemia and immunological diseases .

HY-148585

BTK-IN-22	Btk	Cancer
BTK-IN-22 is a *BTK* inhibitor (IC₅₀: 0.9 nM). BTK-IN-22 also inhibits BLX and BMX with IC₅₀s of 1.4 and 1.2 nM respectively. BTK-IN-22 shows improved kinase selectivity compared to Ibrutinib (HY-10997)

HY-148594

BTK-IN-23	Btk	Cancer
BTK-IN-23 is a *BTK* inhibitor (IC₅₀: 12.8 nM). BTK-IN-23 also inhibits BLX and BMX with IC₅₀s of 35.6 and 5.7 nM respectively. BTK-IN-23 shows improved kinase selectivity compared to Ibrutinib (HY-10997) .

HY-151211

BTK-IN-16	Btk	Inflammation/Immunology Cancer
BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC₅₀s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia .

HY-151920

BTK-IN-17	Btk	Inflammation/Immunology
BTK-IN-17 (compound 36R) is a selective and orally activeBTK inhibitor with an IC₅₀ value of 13.7 nM. BTK-IN-17 decreases the expression of p-BTK ^Y223 and p-PLCγ2 ^Y1217. BTK-IN-17 shows anti-inflammatory effects .

HY-115944

BTK-IN-9	Btk Apoptosis	Inflammation/Immunology Cancer
BTK-IN-9 is a reversible *BTK* inhibitors with potent antiproliferative activity in mantle cell lymphoma. BTK-IN-9 specifically disturbs mitochondrial membrane potential and increases reactive oxygen species level in Z138 cells. BTK-IN-9 also induces cell apoptosis in Z138 cells .

HY-160219S

BTK-IN-33	Btk	Cancer
BTK-IN-33 is a *Btk* inhibitor with anticancer effects (WO2023174300A1; compound I) .

HY-152212

BTK-IN-19	Btk	Inflammation/Immunology
BTK-IN-19 (Compound 51) is a reversible *BTK* inhibitor with an IC₅₀ of <0.001 μM .

HY-171131

BTK-IN-41	Btk	Cancer
BTK-IN-41 (Compound 47) is the inhibitor for *BTK* with an IC₅₀ of 5.4 nM. BTK-IN-41 inhibits the diffuse large B cell lymphoma cell TDM-8 with IC₅₀ of 13.8 nM .

HY-148832

BTK-IN-20	Btk	Inflammation/Immunology Cancer
BTK-IN-20 (compound 283) is a *BTK* tyrosine kinase inhibitor and a 1H-pyrazolo[3,4-d]pyrimidine derivative. BTK-IN-20 can be used for the research of cancer and inflammation .

HY-163295

BTK degrader-1	ADC Payload Btk	Cancer
BTK degrader-1 (compound 1) is a Bruton’s tyrosine kinase (BTK) bifunctional degrader that can be conjugated with CD79b. BTK degrader-1 (compound 1) has anti-tumor effect .

HY-168965

BTK ligand 15	Ligands for Target Protein for PROTAC	Others
BTK ligand 15 is the target protein ligand of PROTAC BTK Degrader-13 (HY-168963). PROTAC BTK Degrader-13 can selectively degrade *BTK* .

HY-115876

BTK-IN-5	Btk	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
BTK-IN-5 is a covalent *BTK* inhibitor for researching medical conditions such as cardiovascular diseases, respiratory diseases, inflammation, and diabetes.

HY-143900

BTK-IN-7	Btk Apoptosis	Inflammation/Immunology Cancer
BTK-IN-7 is a potent and selective inhibitor of *BTK* (IC₅₀=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels (ITK >227-fold, EGFR 27-fold). BTK-IN-7 also has potent antitumor activity .

HY-168302

BTK ligand 10	Ligands for Target Protein for PROTAC Tyrosinase Btk	Cancer
BTK ligand 10 is the ligand of *BTK. BTK* ligand 10 can be used to synthesize NX-2127 (HY-153220) .

HY-173126

BTK ligand-14	Btk Ligands for Target Protein for PROTAC	Others
BTK ligand-14 is a PROTAC target protein ligand that targets *BTK* and can be used for the synthesis of FDU73 (HY-173125) .

HY-132196

BTK inhibitor 18	Btk	Inflammation/Immunology
BTK inhibitor 18 is a potent, selective,orally active and covalent *Btk* inhibitor with a IC₅₀ of 142 nM. BTK inhibitor 18 has anti-inflammatory activities .

HY-143730

BTK inhibitor 20	Btk	Cancer
BTK inhibitor 20 is a potent *BTK* inhibitor with an IC₅₀ of 8 nM .

HY-160168

BTK-IN-31	Btk	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable *Btk* inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders .

HY-145884

BTK-IN-8	Btk	Inflammation/Immunology
BTK-IN-8 is a potent and selective peripheral covalent *BTK* inhibitor (IC₅₀=0.22 nM; K_d=0.91 nM). BTK-IN-8 has good whole blood CD69 cellular potency (IC₅₀=0.029 µM) .

HY-131705

BTK inhibitor 17	Btk	Inflammation/Immunology
BTK inhibitor 17 is a potent and orally active irreversible *BTK* inhibitor with an IC₅₀ of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research .

HY-128403

BTK inhibitor 8	Btk	Inflammation/Immunology
BTK inhibitor 8 (Compound 27) is a *Btk* inhibitor with an IC₅₀ of 0.11 nM. BTK inhibitor 8 inhibits B cell activation in hWB with an IC₅₀ of 2 nM .

HY-142932

BTK-IN-6	Btk	Neurological Disease Inflammation/Immunology Cancer
BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8) .

HY-176526

BTK degrader-1 intermediate	Drug Intermediate Btk	Cancer
BTK degrader-1 intermediate (compound 5) is an intermediate for the synthesis of BTK degrader-1 (HY-163295). BTK degrader-1 can be used as an ADC toxin to synthesize antibody-drug conjugate (ADC) .

HY-173143

BTK-IN-42	Btk	Cancer
BTK-IN-42 (Compound 11a) is a *Btk* inhibitor. BTK-IN-42 can effectively inhibit the growth and migration of tumor cells TMD8, with IC₅₀ values of 2.61 and 5.34 μM for TMD8 and T9 cells respectively. It shows promise for research in the field of anti-cancer .

HY-139881

BTK inhibitor 19	Btk	Cancer
BTK inhibitor 19 is a highly selective, covalent *BTK* inhibitor (IC₅₀ = 2.7 nM).

HY-150885

BTK ligand 1	Ligands for Target Protein for PROTAC Btk	Cancer
BTK ligand 1 (compound 1) is a ligand targeting Bruton’s tyrosine kinase (Btk). BTK ligand 1 can combine with E3 ligase ligand (Ligand for E3 Ligase) through PROTAC Linker to form PROTAC. PROTACs targeting *Btk* can be used in the study of chronic lymphocytic leukemia (CLL) and other BK cell malignancies .

HY-130255

BTK inhibitor 13	Btk	Inflammation/Immunology
BTK inhibitor 13 (compound 8) is a potent and selective Bruton's tyrosine kinase (BTK) inhibitor with an IC₅₀ of 1.2 nM .

Cat. No.	Product Name

HY-L129

Target Protein Ligand Library

60 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 60 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

HY-L156

Autoimmune Disease Compound Library

693 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 693 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

HY-L009

Kinase Inhibitor Library

3,312 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 3,312 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

HY-L009M

Kinase Inhibitor Library Mini

268 compounds

Kinases is a class of enzymes that adds chemicals called phosphates to other molecules, such as sugars or proteins. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes including cell division, metabolism, and signal transduction, with approximately 50% of cellular functions in humans being regulated by kinase activity. In drug discovery, kinases represent a major category of therapeutic targets, and kinase inhibitors constitute an important class of pharmaceuticals that block the activity of specific disease-associated enzymes, particularly in cancer and inflammatory disorders. Small molecule kinase inhibitors represent one of the fastest-growing drug categories, having received U.S. Food and Drug Administration (FDA) approval for both oncological and non-oncological indications. As of September 2023, over 70 FDA-approved small molecule kinase inhibitors are commercially available.

The MCE Kinase Inhibitor Library Mini contains 268 kinase inhibitors primarily targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.), and carbohydrate kinases. This collection includes 1-3 highly specific representative compounds per target, optimized for screening of kinase-related drug targets in pharmaceutical research.

HY-L016

Protein Tyrosine Kinase Compound Library

1,328 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,328 compounds that act as a useful tool for PTKs-related drug screening and disease research.

Cat. No.	Product Name	Type

HY-110002

LFM-A13 1 Publications Verification	Biochemical Assay Reagents
LFM-A13 is a potent *BTK, JAK2, PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research

Cat. No.	Product Name	Target	Research Area

HY-P5438

Srctide	Btk c-Kit FAK FLT3 Insulin Receptor	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P1181A

Pam2CSK4 TFA	Toll-like Receptor (TLR)	Inflammation/Immunology
Pam2CSK4 (TFA), a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 (TFA) promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 (TFA) also activates iNOS expression and NO production in mouse macrophages .

HY-P10609

Btk substrate peptide	Btk	Others
Btk substrate peptide is a peptide substrate corresponding to residues 217-229 of human Bruton’s tyrosine kinase (Btk), of which the tyrosine at residue 223 is the major autophosphorylation site of *Btk. Btk* substrate peptide is used as a substrate in in vitro kinase assays to evaluate the activity of *Btk* or other tyrosine kinases .

HY-P1181

Pam2CSK4	Toll-like Receptor (TLR)	Inflammation/Immunology
Pam2CSK4, a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 also activates iNOS expression and NO production in mouse macrophages .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-110013

Terreic acid	Microorganisms Source classification	Btk Antibiotic
Terreic acid, a quinone epoxide antibiotic, acts as an effective *Btk* inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk. Terreic acid inhibits the binding of GST-BtkPH to PKC in lysates of HMC-1 human mast cells with an IC₅₀ of approximately 100 μM .

Recombinant Proteins Recommended:

Brutons Tyrosine Kinase (BTK)

Species:	Human (9)
Tag:	His (3) Avi (1) GST (1)
Source:	Sf9 insect cells (8) P. pastoris (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P702730

	BTK Protein, Human (Biotinylated, sf9, His, Avi) Btk; Bruton agammaglobulinemia tyrosine kinase; tyrosine-protein kinase Btk;	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (Biotinylated, sf9, His, Avi) is the recombinant human-derived BTK, expressed by Sf9 insect cells , with His, Avi labeled tag. ,

HY-P72048

	BTK Protein, Human (sf9, His) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, His) is the recombinant human-derived BTK protein, expressed by sf9 insect cells , with N-10*His labeled tag.

HY-P704026

	BTK Protein, Human (sf9, GST, C481S) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST, C481S) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704025

	BTK Protein, Human (sf9, GST) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704027

	BTK Protein, Human (sf9, GST, M437R) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST, M437R) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704028

	BTK Protein, Human (sf9, GST, T316A) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST, T316A) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704029

	BTK Protein, Human (sf9, GST, T474I) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST, T474I) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P704030

	BTK Protein, Human (sf9, GST, T474S) Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton Tyrosine Kinase; Btk; Btk_HUMAN; dominant-negative kinase-deficient Brutons tyrosine kinase; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; truncated Bruton agammaglobulinemia tyrosine kinase; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; tyrosine-protein kinase Btk isoform lacking exon 14; XLA	Human	Sf9 insect cells
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (sf9, GST, T474S) is the recombinant human-derived BTK protein, expressed by Sf9 insect cells, with N-GST labeled tag.

HY-P700598

	BTK Protein, Human (P. pastoris, His) Agammaglobulinemia tyrosine kinase ; ATKB-cell progenitor kinase ; BPKBruton tyrosine kinase	Human	P. pastoris
	The BTK protein is a key non-receptor tyrosine kinase that is essential for B lymphocyte development and signaling. After BCR activation, BTK initiates a cascade reaction, phosphorylates PLCG2 and activates downstream pathways, affecting calcium mobilization and PKC activation. BTK Protein, Human (P. pastoris, His) is the recombinant human-derived BTK protein, expressed by P. pastoris , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10997S

Ibrutinib-d5
Ibrutinib-d₅ is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor .

HY-101474S

Zanubrutinib-d5
Zanubrutinib-d₅ is deuterium labeled Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (Btk) inhibitor .

HY-17600S

Acalabrutinib-d4
Acalabrutinib-d₄ is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor . Acalabrutinib-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-153951S

BTK-IN-26
BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC₅₀ values of 0.7 and 0.8 nM for *BTK* and BTK C481S, respectively. BTK-IN-26 can be used for cancer and autoimmune diseases research .

HY-160219S

BTK-IN-33
BTK-IN-33 is a *Btk* inhibitor with anticancer effects (WO2023174300A1; compound I) .

HY-100659S

Dihydrodiol-Ibrutinib-d5
Dihydrodiol-Ibrutinib-d5 is the deuterium labeled Dihydrodiol-Ibrutinib (HY-100659). Dihydrodiol-Ibrutinib is a dihydrodiol active metabolite of Ibrutinib (HY-10997), has inhibitory activity towards *BTK* approximately 15 times lower than that of ibrutinib .

HY-W757743

Acalabrutinib-d3
Acalabrutinib-d₃ (ACP-196-d₃) is the deuterated form of Acalabrutinib (HY-17600). Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows strong targeting and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

HY-101474BS

(R)-Zanubrutinib-d5
(R)-Zanubrutinib-d₅ is deuterium labeled (R)-Zanubrutinib. (R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.

HY-135334S

ACP-5862-d4

ACP-5862-d₄ is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC₅₀ of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC₅₀ of 3 nM and EC₅₀ of 8 nM .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80576

	BTK Antibody (YA816) Btk; AGMX1; ATK; BPK; Tyrosine-protein kinase Btk; Agammaglobulinaemia tyrosine kinase; ATK; B-cell progenitor kinase; BPK; Bruton tyrosine kinase	WB, IP	Human
	BTK Antibody (YA816) is a non-conjugated and Mouse origined monoclonal antibody about 76 kDa, targeting to BTK (5B12). It can be used for WB,IP assays with tag free, in the background of Human.

HY-P80454

	*Phospho-BTK(Y223) Antibody (YA221)* Btk(Y223); Btk (phospho Y223); p-Btk (phospho Y223); Agammaglobulinaemia tyrosine kinase; AGMX 1; AGMX1; AT; ATK; B cell progenitor kinase; B-cell progenitor kinase; BPK; Bruton agammaglobulinemia tyrosine kinase; Bruton tyrosine kinase; Bruton’s Tyrosine Kinase; Btk; Btk_HUMAN; IMD 1; IMD1; MGC126261; MGC126262; OTTHUMP00000063593; PSCTK 1; PSCTK1; Tyrosine protein kinase Btk; Tyrosine-protein kinase Btk; XLA.	WB, IP	Human
	Phospho-BTK(Y223) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 76 kDa, targeting to Phospho-BTK(Y223). It can be used for WB, IP assays with tag free, in the background of Human.

HY-P84493

	BTK Antibody (YA4190) Btk	WB, IHC-P, ICC/IF, ELISA	Human, Monkey
	BTK Antibody (YA4190) is a mouse-derived and non-conjugated IgG1 antibody, targeting to BTK. It can be applicated for WB, IHC-P, ICC/IF, ELISA assays, in the background of human, monkey.

HY-P86215

	BTK Antibody (YA5907) Btk; AGMX1; ATK; BPK; Tyrosine-protein kinase Btk; Agammaglobulinaemia tyrosine kinase; ATK; B-cell progenitor kinase; BPK; Bruton tyrosine kinase	WB, IHC-P, ICC/IF, IP, ELISA	Human
	BTK Antibody (YA5907) is a rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BTK. It can be applicated for WB, IHC-P, ICC/IF, IP, ELISA assays, in the background of human.

HY-P83523

	General Transcription Factor II I Antibody (YA3268) GTF2I; BAP135; WBSCR6; General transcription factor II-I; GTFII-I; TFII-I; Bruton tyrosine kinase-associated protein 135; BAP-135; Btk-associated protein 135; SRF-Phox1-interacting protein; SPIN; Williams-Beuren syndrome chromosomal region	WB, IHC-F, IHC-P, ICC/IF	Human
	General Transcription Factor II I Antibody (YA3268) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3268), targeting General Transcription Factor II I, with a predicted molecular weight of 112 kDa (observed band size: 135/138 kDa). General Transcription Factor II I Antibody (YA3268) can be used for WB, IHC-F, IHC-P, ICC/IF experiment in human background.